Drug Approval | March 07, 2024
Sakar's oncology unit receives EU GMP approval
The WHO GMP approved vertically integrated ONCOLOGY unit of SAKAR has been selling products nationally since few quarters
The WHO GMP approved vertically integrated ONCOLOGY unit of SAKAR has been selling products nationally since few quarters
Acquisition of exclusive commercialization rights for European markets
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
BHL will undertake the development and supply of these molecules
MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
The R&D centre is mainly dedicated to the Process R&D of New Chemical Entities (NCE) development projects
Subscribe To Our Newsletter & Stay Updated
